Related Experiment Videos
Epidermal growth factor receptor expression in normal and malignant endometrium.
A Berchuck1, A P Soisson, G J Olt
1Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27710.
American Journal of Obstetrics and Gynecology
|November 1, 1989
Summary
Epidermal growth factor receptor (EGFR) is present in most normal uterine cells. However, EGFR expression is significantly reduced in many endometrial adenocarcinomas, suggesting a potential role in cancer development.
Area of Science:
- Gynecology
- Oncology
- Molecular Biology
Background:
- Epidermal growth factor receptor (EGFR) plays a role in cell growth and differentiation.
- Aberrant EGFR signaling is implicated in various cancers, including endometrial cancer.
Purpose of the Study:
- To investigate the expression patterns of EGFR in normal uterine tissues and endometrial adenocarcinomas.
- To determine if EGFR expression correlates with clinicopathological features of endometrial cancer.
Main Methods:
- Fresh-frozen uterine tissues were analyzed using immunohistochemistry.
- Monoclonal antibody 528 was employed to detect EGFR on the external domain.
- Staining intensity and distribution were evaluated in normal endometrium, myometrium, and endometrial adenocarcinomas.
Main Results:
- EGFR was detected in all cell types of 19 out of 20 normal uteri.
- Endometrial glands and stroma showed higher EGFR staining than myometrium.
- EGFR was less frequent in endometrial adenocarcinomas (32.5% lacked detectable receptor) compared to normal endometrium (p < 0.01).
- No correlation was found between EGFR expression and tumor grade, invasion depth, hormone receptor status, metastasis, or recurrence.
Conclusions:
- EGFR is widely expressed in normal uterine tissues.
- Reduced EGFR expression is observed in a significant subset of endometrial adenocarcinomas.
- EGFR status does not appear to be a prognostic marker for endometrial cancer based on these clinicopathological factors.